Screener
Tarsus Pharmaceuticals, Inc.
TARSTarsus Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for high unmet medical needs, with an initial focus on eye care.
Earnings
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$183.7M
EPS estimate-$1.43
Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
HRO
Harrow+21.1%
By net margin
HRO
Harrow-19.75%+4.4ppProfile
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for high unmet medical needs, with an initial focus on eye care. The company's core value proposition centers on its proprietary lotilaner-based platform, which targets and eradicates parasite infestations to treat inflammatory and infectious diseases.
Competitive position
Tarsus holds a first-mover advantage with the only FDA-approved therapeutic for Demodex blepharitis.
GeographiesUnited States
Customer segmentsHealthcare Providers, Patients
Business modelR&D-based drug development, Direct pharmaceutical sales
SuppliersActive pharmaceutical ingredient (API) manufacturers, Contract Research Organizations (CROs), Specialized chemical suppliers
CustomersSpecialty pharmacies, Pharmaceutical wholesalers, Hospitals and clinics
CountryUnited States of America
Listed2020
Employees244.0
CEOBobak R. Azamian
SectorHealthcare
IndustryBiotechnology
Websitetarsusrx.com
FilingsSEC EDGAR
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s market cap?
- Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $3.6B and trades on NASDAQ.
- What is Tarsus Pharmaceuticals, Inc.'s revenue and profitability?
- Tarsus Pharmaceuticals, Inc. generated $606.3M in trailing twelve-month revenue with a net loss of $46.5M, representing a net margin of -7.7%. Gross margin stands at 79.8%, with free cash flow of -$24.9M. The latest reported period is Q2 2026.
- Who are Tarsus Pharmaceuticals, Inc.'s competitors?
- Tarsus Pharmaceuticals, Inc.'s key competitors include Bausch + Lomb, Alcon, AbbVie, and others. These companies compete in similar markets and product categories.
- Where is Tarsus Pharmaceuticals, Inc. headquartered?
- Tarsus Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 244 people. It has been publicly traded since 2020.
